drugset / Trial / NCT02182843

Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM/MaxAn)

NCT02182843 ↗

Completed 81 enrolled Zimmer Biomet
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the clinical and radiographic outcomes in patients who undergo ACDF procedures using Cellentra Viable Cell Bone Matrix (VCBM), cortical allograft spacers, and the MaxAn® Anterior Cervical Plate System. Cellentra VCBM will be compared to published data for autograft in NDI (Neck Disability Index) improvement and radiographic success of fusion.

Timeline

Start
2014-03
Primary completion
2018-01
Completion
2018-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cellentra™ VCBM Unknown — —